Do we need to adjudicate major clinical events?

Clinical Trials

Volumn 5, Issue 5, 2008, Pages 557-

  Meinert, Curtis L ^a   Martin, Barbara K ^a   McCaffrey, Lee D ^a   Breitner, John C S ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; NAPROXEN; PLACEBO;

ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; LONG TERM CARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; DECISION MAKING; DRUG THERAPY; HUMANS; MULTICENTER STUDIES AS TOPIC; PUBLISHING; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 59349120533     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774508096007     Document Type: Letter

References (4)

1. Granger CB, Vogel V., Cummings SR, et al. Do we need to adjudicate major clinical events? Clinical Trials 2008; 5: 56-60.
2. Meinert CL, Brietner JCS. Chronic disease long-term drug prevention trials: Lessons from the Alzheimer's Disease Anti-inflammatory Trial (ADAPT). Alzheimer's & Dementia 2008; 4: S7-S14.
3. ADAPT Research Group: Cardiovascular and cerebrovascular results from the randomized, controlled Alzheimer's disease anti-inflammatory prevention trial (ADAPT). PLoS Clin Trials 2006; 1 (7): E33. doi:10.1371/ journal.pctr.
4. Solomon SD, Wittes J., Finn PV, et al. for the Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis. Circulation 2008; 117: 2104-13.